OliX Collaboration (siRNA)

About Key2Brain

Key2Brain is a private, preclinical-stage biotech developing a versatile platform for delivering therapeutics across the blood-brain barrier. Its technology employs small, engineered VHH antibodies targeting the TfR to shuttle biologics, including peptides, proteins, enzymes, monoclonal antibodies, and oligonucleotides, into the brain. The company has secured notable partnerships with firms like OliX Pharmaceuticals and Chiesi Group and has received non-dilutive grant funding from VINNOVA, positioning it as an emerging enabler in the challenging field of CNS drug delivery.

Therapeutic Areas

Other Undisclosed CNS Target Drugs